Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Forest To Acquire Specialty Pharma Firm
by Lisa M. Jarvis
January 13, 2014
| A version of this story appeared in
Volume 92, Issue 2
Forest Laboratories will shell out $2.9 billion in cash to acquire privately held specialty pharmaceuticals firm Aptalis. The deal for Aptalis, which had sales of $688 million in fiscal 2013, diversifies Forest’s product portfolio into gastrointestinal and cystic fibrosis treatments. Forest, which recently unveiled plans to cut 9% of its workforce as it struggles with generics competition for its antidepressant Lexapro, believes it can achieve $125 million in cost synergies between the two companies. The deal is expected to close in the first half of this year.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter